Tech Company Financing Transactions
Imara Inc. Funding Round
On 3/19/2019, Imara Inc. secured $63 million in Series B investment from Arix Bioscience, OrbiMed and Alexandria Venture Investments.
Transaction Overview
Company Name
Announced On
3/19/2019
Transaction Type
Venture Equity
Amount
$63,000,000
Round
Series B
Investors
Arix Bioscience (Lead Investor) (Mark Chin)
OrbiMed (Lead Investor) (David Bonita)
Proceeds Purpose
Proceeds from the investment will be used to advance the company's lead program with IMR-687, currently in a multi-national Phase 2a clinical trial, into later-stage clinical trials, fund development of IMR-687 as a potential treatment for thalassemia, and expand the company's pipeline.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
700 Technology Sq. 3rd Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Overview
Imara Inc. (Nasdaq: IMRA), is dedicated to developing novel therapeutics for people living with sickle cell disease and other hemoglobinopathies. Sickle cell disease is a rare, genetic blood disease that causes red blood cells to sickle and become damaged, activating immune cells and blocking blood flow in capillaries, injuring many organs and causing daily pain.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Rahul Ballal
Chief Medical Officer
ShiYin Foo
VP - Regulatory Affairs
Kevin Johnson
Browse more venture capital transactions:
Prev: 3/19/2019: Glossier venture capital transaction
Next: 3/19/2019: Ocular Therapeutix venture capital transaction
Share this article
Where The Data Comes From
We report on funding rounds that are announced publicly. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs